Lohocla Research Corporation is a privately held corporation established 2000 with funding from its founder and NIH-SBIR grant support. Domiciled in Illinois, operations are based in Colorado. Lohocla is currently supported by a $7.6 million NIH medications-development grant for treatment of alcohol addiction (lead molecule, “Nezavist”) from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and a UG3/UH3 grant from the National Institute on Drug Abuse (NIDA). The NIDA award is for $15.3 million over five years, to bring the company’s chronic pain- and opiate-sparing medication, “Kindolor,” through Phase 1 trials. The first stage of the NIDA award provided $5.6 million for preclinical studies resulting in an IND application. The second stage provides $9.7 million for the completion of Phase 1a and 1b clinical studies.
Lohocla Research Corporation is presenting as part of the NIH Innovation Zone.